세계의 골다공증 치료제 시장 규모 조사 및 예측 : 약물 유형별(부갑상선 호르몬 요법, 비스포스포네이트, 칼시토닌, RANKL 억제제, 기타 약물 유형), 투여 경로별(경구용, 주사제, 기타), 지역별 분석(2023-2030년)

Global Osteoporosis Drugs Market is valued at approximately USD 8.93 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2023-2030. Osteoporosis is a medical condition that is characterized by low bone quality and density in humans. Additionally, this health issue causes the bones to become porous, which makes them more brittle and susceptible to fractures. The disorder is caused by an excess of the hormone parathyroid. The condition results in serious fractures, which are harmful to the patient's health. Because of this, the problem needs to be treated, which involves taking medications for osteoporosis. RANK ligand inhibitors, parathyroid hormone treatment, calcitonin, and selective estrogen inhibitors modulators (SERM) are several medications available in the market. These medications are administered in ways including orally and intravenously. The surge in the geriatric population, adoption of a sedentary lifestyle, increasing healthcare expenditure, and rise in hip fractures are the several factors that are propelling the market demand during the estimated period.

In addition, the increase in the incidences of osteoporosis is playing a major role that is stipulating market growth across the globe. The prevalence of osteoporosis is increasing due to changing lifestyle habits, lack of physical activity, and poor diet. This has led to an increase in the demand for osteoporosis drugs. The International Osteoporosis Foundation stated that in 2020, 1 in 5 men and 1 in 3 women more than the age of 50 are likely to experience osteoporosis fractures in their life. Additionally, according to the International Osteoporosis Foundation (IOF), in 2019, the annual number of osteoporotic fractures in Europe accounted for 4.28 million, which is projected to increase and reach 5.34 million in 2034. The percentage growth during the 15-year period is likely to differ significantly by nation, from a low 8% growth (Latvia) to 58% (Ireland). Also, as per the National Osteoporosis Foundation (NOF), in 2020, over 10 million people in the United States have been diagnosed with osteoporosis, which is common in menopausal women. Consequentially, the rising cases of osteoporosis are significantly contributing to the market expansion. Moreover, the high growth prospects in emerging markets, as well as the increasing investment in R&D activities present various lucrative opportunities over the forecasting years. However, the stringent regulations on the drug approval process and the side effects of osteoporosis drugs are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Osteoporosis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surge in the incidence of osteoporosis, the presence of key players, and growing R&D investment. Whereas, Asia Pacific is expected to grow at the fastest growing over the forecasting years. The growing awareness regarding the use of osteoporosis drugs, rising government initiatives, increase in hip fractures, changing lifestyle, and growing demand for generic drugs are significantly propelling the market demand across the region.

Major market players included in this report are:

• Amgen Inc.
• Eli Lilly and Company
• F. HOFFMANN-LA ROCHE LTD.
• Radius Health, Inc.
• Merck & Co. Inc.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Recent Developments in the Market:

• In August 2021, The Drug Controller General of India (DCGI) granted Enzene Biosciences Ltd. marketing authorization (MA) for their biosimilar medication, denosumab, which is approved for the treatment of adult osteoporosis.

Global Osteoporosis Drugs Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drug Type, Route of Administration, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• RANKL Inhibitors
• Other Drug Types

By Route of Administration:

• Oral
• Injectable
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Osteoporosis Drugs Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Osteoporosis Drugs Market, by Drug Type, 2020-2030 (USD Billion)
  • 1.2.3. Osteoporosis Drugs Market, by Route of Administration, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Osteoporosis Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Osteoporosis Drugs Market Dynamics

• 3.1. Osteoporosis Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increase in the incidences of osteoporosis
    • 3.1.1.2. Rising hip fractures
  • 3.1.2. Market Challenges
    • 3.1.2.1. Stringent regulations on drug approval process
    • 3.1.2.2. Side effects of osteoporosis drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. High growth prospects in emerging markets
    • 3.1.3.2. Increasing investment in the R&D activities

Chapter 4. Global Osteoporosis Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Osteoporosis Drugs Market, by Drug Type

• 5.1. Market Snapshot
• 5.2. Global Osteoporosis Drugs Market by Drug Type, Performance - Potential Analysis
• 5.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Drug Type 2020-2030 (USD Billion)
• 5.4. Osteoporosis Drugs Market, Sub Segment Analysis
  • 5.4.1. Parathyroid Hormone Therapy
  • 5.4.2. Bisphosphonates
  • 5.4.3. Calcitonin
  • 5.4.4. RANKL Inhibitors
  • 5.4.5. Other Drug Types

Chapter 6. Global Osteoporosis Drugs Market, by Route of Administration

• 6.1. Market Snapshot
• 6.2. Global Osteoporosis Drugs Market by Route of Administration, Performance - Potential Analysis
• 6.3. Global Osteoporosis Drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 6.4. Osteoporosis Drugs Market, Sub Segment Analysis
  • 6.4.1. Oral
  • 6.4.2. Injectable
  • 6.4.3. Others

Chapter 7. Global Osteoporosis Drugs Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Osteoporosis Drugs Market, Regional Market Snapshot
• 7.4. North America Osteoporosis Drugs Market
  • 7.4.1. U.S. Osteoporosis Drugs Market
    • 7.4.1.1. Drug Type breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Osteoporosis Drugs Market
• 7.5. Europe Osteoporosis Drugs Market Snapshot
  • 7.5.1. U.K. Osteoporosis Drugs Market
  • 7.5.2. Germany Osteoporosis Drugs Market
  • 7.5.3. France Osteoporosis Drugs Market
  • 7.5.4. Spain Osteoporosis Drugs Market
  • 7.5.5. Italy Osteoporosis Drugs Market
  • 7.5.6. Rest of Europe Osteoporosis Drugs Market
• 7.6. Asia-Pacific Osteoporosis Drugs Market Snapshot
  • 7.6.1. China Osteoporosis Drugs Market
  • 7.6.2. India Osteoporosis Drugs Market
  • 7.6.3. Japan Osteoporosis Drugs Market
  • 7.6.4. Australia Osteoporosis Drugs Market
  • 7.6.5. South Korea Osteoporosis Drugs Market
  • 7.6.6. Rest of Asia Pacific Osteoporosis Drugs Market
• 7.7. Latin America Osteoporosis Drugs Market Snapshot
  • 7.7.1. Brazil Osteoporosis Drugs Market
  • 7.7.2. Mexico Osteoporosis Drugs Market
• 7.8. Middle East & Africa Osteoporosis Drugs Market
  • 7.8.1. Saudi Arabia Osteoporosis Drugs Market
  • 7.8.2. South Africa Osteoporosis Drugs Market
  • 7.8.3. Rest of Middle East & Africa Osteoporosis Drugs Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Amgen Inc.
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. Eli Lilly and Company
  • 8.3.3. F. HOFFMANN-LA ROCHE LTD.
  • 8.3.4. Radius Health, Inc.
  • 8.3.5. Merck & Co. Inc.
  • 8.3.6. Novartis International AG (Sandoz)
  • 8.3.7. Pfizer Inc.
  • 8.3.8. Sun Pharmaceutical Industries Ltd.
  • 8.3.9. Takeda Pharmaceutical Company Limited
  • 8.3.10. Teva Pharmaceutical Industries Ltd.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption